COMP <GO>
MEDP vs IQV // EV/EBITDA & P/E VALUATION
Medpace Holdings Inc. (NASDAQ) VS. IQVIA Holdings Inc. (NYSE) • 15-METRIC TALLY: MEDP 7
— IQV 5
▲ EV/EBITDA & P/E VALUATION LEADER: IQV
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
valuation
34.0x
LAST: $267.33 (-2.81%) • MKT CAP: $45.33B
valuation
20.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. IQV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | IQV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.90% | 9.40% | +18.50 | MEDP | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 34.0x | 20.4x | +13.60 | IQV | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 4.24% | -0.64 | IQV | /fcf-yield <GO> |
| Operating Margin | 21.10% | 13.40% | +7.70 | MEDP | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 8.30% | +9.50 | MEDP | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 5.90% | +14.10 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.13 | 2.22 | +6.91 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | MEDP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.2 | 55.7 | +5.50 | MEDP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.16 | -0.16 | IQV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 31.0x | +4.30 | IQV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.95B | $45.33B | -$26.38B | IQV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | IQV REV | MEDP GROSS % | IQV GROSS % | MEDP FCF | IQV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $16.31B | — | — | $681.9M | $1.92B |
| FY 2024 | $2.11B | $15.40B | — | — | $572.3M | $2.02B |
| FY 2023 | $1.89B | $14.98B | — | — | $348.5M | $1.47B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
IQV // BETA 1.16